Skip to main content

Advertisement

SpringerLink
Log in

Guidance for the adjustment of FRAX according to the dose of glucocorticoids

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

We examined the effect of glucocorticoid dose on FRAX® derived fracture probabilities in a UK setting. A relatively simple adjustment of conventional FRAX estimates of probabilities of hip fracture and a major osteoporotic fracture can be applied to modulate the risk assessment with knowledge of the dose of glucocorticoids.

Introduction

The WHO fracture risk assessment (FRAX) tool estimates 10-year probability of fracture based upon multiple clinical risk factors and an optional femoral neck BMD measurement. Ever (past and current) use of systemic glucocorticoids is a dichotomous risk factor (yes/no) and does not therefore take account of the dose of glucocorticoids. The aim of this work was to estimate the adjustment for fracture probability based upon the dose of glucocorticoids.

Methods

Dose responses for fracture risk during exposure to glucocorticoids were taken from the General Practice Research Database and used to adjust the relative risks for glucocorticoids in FRAX. In addition to fracture risk, a dose response for the death hazard was estimated and both variables were used to populate the FRAX model for the UK.

Results

The exposure to glucocorticoids was found to significantly affect fracture probability. The following rule was formulated. For low-dose exposure (<2.5 mg daily of prednisolone or equivalent), the probability of a major fracture is decreased by about 20% depending on age. For medium doses (2.5–7.5 mg daily), the unadjusted FRAX value can be used. For high doses (>7.5 mg daily), probabilities can be upward revised by about 15%. Conversion factors were also determined for the adjustment of hip fracture probability.

Conclusion

A relatively simple adjustment of conventional FRAX estimates of probabilities of hip fracture and a major osteoporotic fracture can be applied to modulate the risk assessment with knowledge of the dose of glucocorticoids.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Kanis JA on behalf of the World Health Organization Scientific Group (2008) Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK. Accessed at www.shef.ac.uk/FRAX/

  2. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397

    Article  CAS  PubMed  Google Scholar 

  3. Kanis JA, Oden A, Johnell O et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046

    Article  CAS  PubMed  Google Scholar 

  4. Kanis JA, Burlet N, on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428

    Article  CAS  PubMed  Google Scholar 

  5. Fujiwara S, Nakamura T, Orimo H et al (2008) Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX™). Osteoporos Int 19:429–448

    Article  CAS  PubMed  Google Scholar 

  6. Dawson-Hughes B (2008) A revised clinician’s guide to the prevention and treatment of osteoporosis. J Clin Endocrinol Metab 93:2463–2465

    Article  CAS  PubMed  Google Scholar 

  7. National Osteoporosis Foundation (2008) Clinician’s guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation. www.nof.org

  8. Neuprez A, Johansson H, Kanis JA et al (2009) Rationalisation du remboursement des médicaments de l’ostéoporose : de la mesure isolée de la densité osseuse à l’intégration des facteurs cliniques de risque fracturaire. Validation de l’algorithme FRAX®. La Revue Médicale de Liège 64 : 12 : 612–619

  9. Lippuner K, Johansson H, Kanis JA, Rizzoli R (2010) FRAX® assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int 21:381–390

    Article  PubMed  Google Scholar 

  10. Czerwinski E, Kanis JA, Trybulec B, Johansson H, Borowy P, Osieleniec J (2009) The incidence and risk of hip fracture in Poland. Osteoporos Int 20:1363–1368

    Article  CAS  PubMed  Google Scholar 

  11. Berry SD, Kiel DP, Donaldson MG, Cummings SR, Kanis JA, Johansson H, Samelson EJ (2010) Application of the national osteoporosis foundation guidelines to postmenopausal women and men: the Framingham osteoporosis study. Osteoporos Int 21:53–60

    Article  CAS  PubMed  Google Scholar 

  12. Grossman JM, Gordon R, Ranganath VK et al (2010) American college of rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 62:1515–1526

    Article  Google Scholar 

  13. Papaioannou A, Morin S, Cheung AM et al (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182:1864–1873.

    Google Scholar 

  14. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A (2008) Case finding for the management of osteoporosis with FRAX®-assessment and intervention thresholds for the UK. Osteoporos Int 19:1395–1408

    Article  CAS  PubMed  Google Scholar 

  15. Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P, Wilkins M; on behalf of the National Osteoporosis Guideline Group (NOGG) (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62:105–108

    Article  Google Scholar 

  16. Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E (2009) FRAX® and its applications to clinical practice. Bone 44:734–743

    Article  PubMed  Google Scholar 

  17. Roux C, Thomas T (2009) Optimal use of FRAX. Joint Bone Spine 76:1–3

    Article  PubMed  Google Scholar 

  18. Kayan K, Johansson H, Oden A et al (2009) Can fall risk be incorporated into fracture risk assessment algorithms: a pilot study of responsiveness to clodronate. Osteoporos Int 20:2055–2062

    Article  CAS  PubMed  Google Scholar 

  19. Law MR, Hackshaw AK (1997) A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. Br Med J 315:841–846

    CAS  Google Scholar 

  20. Kanis JA, Johnell O, Oden A et al (2005) Smoking and fracture risk: a meta-analysis. Osteoporos Int 16:155–162

    Article  CAS  PubMed  Google Scholar 

  21. Kanis JA, Johansson H, Johnell O et al (2005) Alcohol intake as a risk factor for fracture. Osteoporos Int 16:737–742

    Article  PubMed  Google Scholar 

  22. Delmas PD, Genant HK, Crans GG et al (2003) Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33:522–532

    Article  CAS  PubMed  Google Scholar 

  23. Lunt M, O’Neill TW, Felsenberg D et al (2003) Characteristics of a prevalent vertebral deformity predict subsequent vertebral fracture: results from the European Prospective Osteoporosis Study (EPOS). Bone 33:505–513

    Article  PubMed  Google Scholar 

  24. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739

    Article  CAS  PubMed  Google Scholar 

  25. Hodsman AB, Leslie WD, Tsang JF, Gamble GD (2008) 10-year probability of recurrent fractures following wrist and other osteoporotic fractures in a large clinical cohort: an analysis from the manitoba bone density program. Arch Intern 168:2261–2267

    Article  Google Scholar 

  26. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000

    Article  PubMed  Google Scholar 

  27. Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C (2000) Fracture and oral corticosteroids: relationship to daily and cumulative dose. Rheumatol 39:1383–1389

    Article  Google Scholar 

  28. Van Staa TP, Abenhaim L, Cooper C, Zhang B, Leufkens HG (2001) Public health impact of adverse bone effects of oral corticosteroids. Br J Clin Pharmacol 51:601–607

    Article  PubMed  Google Scholar 

  29. Van Staa TP, Leufkens HGM, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787

    Article  PubMed  Google Scholar 

  30. DeLusignan S, Valentin T, Chan T et al (2004) Problems with primary care data quality: osteoporosis as an exemplar. Inform Prim Care 12:147–156

    Google Scholar 

  31. Steinbuch M, Youket T, Cohen S (2004) Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int 15:323–328

    Article  CAS  PubMed  Google Scholar 

  32. Kanis JA, Johansson H, Oden A et al (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893–899

    Article  PubMed  Google Scholar 

  33. Schols AMWJ, Wesseling G, Kester ADM, de Vries G, Mostert R, Slangen J, Wouters EFM (2001) Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids. Eur Respir J 17:337–342

    Article  CAS  PubMed  Google Scholar 

  34. Sihvonen S, Korpela M, Mustonen J, Huhtala H, Karstila K, Pasternack A (2006) Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids. A population-based cohort study. J Rheumatol 33:1740–6

    CAS  PubMed  Google Scholar 

  35. Wei L, MacDonald TM, Walker BR (2004) Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 141:764–770

    PubMed  Google Scholar 

  36. Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Oglesby A (2002) International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res 17:1237–1244

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK

    J. A. Kanis, H. Johansson, A. Oden & E. V. McCloskey

Authors
  1. J. A. Kanis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Johansson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Oden
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. V. McCloskey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. A. Kanis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kanis, J.A., Johansson, H., Oden, A. et al. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22, 809–816 (2011). https://doi.org/10.1007/s00198-010-1524-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-010-1524-7

Keywords

Search

Navigation